Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS Vaccines
Studies from University of Reading further understanding of HIV/AIDS vaccines
October 29th, 2008
Research findings, 'Mapping the immune response to the outer domain of a human immunodeficiency virus-1 clade C gp120,' are discussed in a new report. "The outer domain (OD) of human immunodeficiency virus (HIV)-1 gp120 represents an attractive, if difficult, target for a beneficial immune response to HIV infection. Unlike the entire gp120, the OD is structurally stable and contains the surfaces that interact with both the primary and secondary cellular receptors," scientists writing in the Journal of General Virology report. "The primary strain-specific neutralizing target, the V3 loop, lies within the OD, as do epitopes for two cross-reactive neutralizing...
Source: Vaccine Weekly (2008-10-29)
|
